Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes
Year: 2020
Type: article
Study design: Observational Study
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: American Diabetes Association, Amgen, AstraZeneca, Patient-Centered Outcomes Research Institute, University of North Carolina, Novo Nordisk, National Institutes of Health, National Institute on Aging, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: Methods for Estimating Sex Differences in Safety and Effectiveness of Drugs, Patterns of use, comparative effectiveness, and safety of rotavirus vaccines, Final clinical studies for submission of a pre-market approval application to the FDA for a Bionic Pancreas that automates type 1 diabetes management, Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study, North Carolina Translational and Clinical Science Institute (NC TraCS), PROMIS Validation in Prospective Population-based Prostate Cancer Research Study, Digestive Disease Epidemiology Training Program, Endocrinology and Metabolism Training Program, Propensity scores and preventive drug use in the elderly, Center for Identification and Study of Individuals with Atypical Diabetes Mellitus, North Carolina Diabetes Research Center
OpenAlex ID: W3047257987